Partial and significant reversal of progressive visual and neurological deficits in multiple sclerosis: A possible therapeutic effect

Clinical and Experimental Ophthalmology

Volumn 30, Issue 5, 2002, Pages 363-366

  Milder, Dan G ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b NONE   (Australia)

Author keywords

Azathioprine; Deficits; Glatiramer acetate; Multiple sclerosis; Progressive; Reversal

Indexed keywords

AZATHIOPRINE; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PAROXETINE; PREDNISONE; PROPANTHELINE BROMIDE; RISPERIDONE; STEROID; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CASE REPORT; CEREBELLUM DISEASE; CHRONIC FATIGUE SYNDROME; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FINGER; FUNCTIONAL ASSESSMENT; HUMAN; JOGGING; LIVER FUNCTION TEST; MICTURITION DISORDER; MOVEMENT PERCEPTION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PSYCHOSIS; REHABILITATION MEDICINE; TREMOR; VISUAL ACUITY; VISUAL IMPAIRMENT; WALKING;

ADULT; AZATHIOPRINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; PEPTIDES; VISION DISORDERS; VISUAL ACUITY;

EID: 0036798626     PISSN: 14426404     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-9071.2002.00566.x     Document Type: Article

References (10)

1. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133-46.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
3. Johnson KP, Brooks BR, Ford CC et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Multiple Sclerosis 2000; 6: 255-66.
4. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicentre, randomised, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
5. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
6. Yudkin PL, Ellison GW, Ghezzi A et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-5.
7. Havrdova E, Ticha V, Novakova I et al. Intramuscular Interferon Beta 1A in combination with azathioprine and low dose steroids: preliminary results of a 2-year double blind, randomised, placebo-controlled study. Poster P-191. European Committee for Treatment and Research in Multiple Sclerosis Conference, Dublin, Ireland, September, 2001.
8. Markovic-Plese S, Bielekova B, Kadom N. et al. Longitudinal magnetic resonance imaging study on the effect of azathioprine in relapsing-remitting multiple sclerosis refractory to the treatment with interferon beta-1b. Poster. American Academy of Neurology, Denver, Colorado, USA, 2002.
9. Mathews PM, Pioro E, Narayanan S et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996; 119: 715-22.
10. Prineas JW, Kwon EE, Cho ES et al. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 2001, 50: 646-57.